CompletedPhase 1ACTRN12605000518662
A pharmacokinetic phase I study to assess the effect of different application sites on the pharmacokinetics of testosterone from a Testosterone Metered Dose (MD) Lotion in hypogonadism.
Sponsor
Acrux DDS Pty Ltd
Enrollment
12 participants
Start Date
Mar 1, 2005
Study Type
Interventional
Conditions
Eligibility
Sex: Females
Plain Language Summary
Simplified for easier understanding
This is an early-phase study looking at: A pharmacokinetic phase I study to assess the effect of different application sites on the pharmacokinetics of testosterone from a Testosterone Metered Dose (MD) Lotion in hypogonadism.. It may be open to women. Key requirements include: Healthy female volunteers Participation typically involves medical assessments and follow-up visits as part of the research.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Testosterone Metered Dose (MD) Lotion. single dose (i.e. one dose)
Testosterone Metered Dose (MD) Lotion. single dose (i.e. one dose)
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12605000518662
Related Trials
Inherited Reproductive Disorders
NCT015004472 locations
Male Experiences With Intra Cytoplasmic Sperm Injection (ICSI) and Reduced Sperm Quality
NCT075464351 location
Observation of Environment and Reproductive-Endocrine Effects
NCT062808071 location
The Effect of Sex Steroid Replacement Therapy in the Hypogonadism and Transgender Active-Duty Population
NCT062472671 location
IMmune checkPoint inhibitor related gonAdal toxiCiTy in premenopausal women and men with melanoma – the IMPACT study
ACTRN126250003954376 locations